课题基金 / 基金详情

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
俄亥俄州立大学作为实验治疗临床试验网络的牵头学术组织 (LAO)
批准号:
10393089
负责人:
SUSANNE M ARNOLD
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-05-12 至 2023-02-28

项目摘要

项目成果

SUSANNE M ARNOLD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY The LAO OH-007 UM1 research group consists of an experienced and innovative multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer utilizing the resources available through CTEP NCI. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with strong collaborations between experienced investigators from multiple oncologic disciplines and a vibrant pattern of discovery in the basic sciences. The present consortium includes OSUCCC in collaboration with the University of Kentucky Markey Cancer Center (MCC) and the University of Utah Huntsman Cancer Institute (HCI) with whom they have had strong relationships in the past, and the University of North Carolina Lineberger Comprehensive Cancer Center (UNC LCCC) who joined LAO OH-007 one year ago. This application is being submitted to request additional funds for UNC, an Affiliated Organization to OSU, an ETCTN UM1 Lead Academic Organization. The funds will allow UNC to continue to participate in the ETCTN including leadership of two ETCTN studies led by Drs. Claire Dees and Joshua Zeidner (described in more detail below), continued accrual to ETCTN studies and participating in other activities including LOI submission and PTMA applications. The present proposal contains a request for funds to support the efforts of two research coordinators and two investigators. Going forward, there will be a continued concerted effort to incorporate the UNC LCCC group into the daily workings of its new home LAO so that study accrual and scientific discovery at this institution can be supported and enhanced. This consortium is committed to accruing a minimum of 100 patients per year to ETCTN studies and it is foreseen that the addition of the UNC LCC phase I group will contribute to this goal in a significant manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation of deoxynucleosides as a novel resistance mechanism for radiotherapy
  • 批准号:
    10336852
  • 项目类别:
  • 资助金额:
    $12.5万
  • 财政年份:
    2014
  • 负责人:
    SUSANNE M ARNOLD
  • 依托单位:
The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
  • 批准号:
    10784839
  • 项目类别:
  • 资助金额:
    $172.26万
  • 财政年份:
    2014
  • 负责人:
    SUSANNE M ARNOLD
  • 依托单位:
Clinical Protocol and Data Management
  • 批准号:
    10204901
  • 项目类别:
  • 资助金额:
    $20.91万
  • 财政年份:
    2013
  • 负责人:
    SUSANNE M ARNOLD
  • 依托单位:
Clinical Protocol and Data Management
  • 批准号:
    10470122
  • 项目类别:
  • 资助金额:
    $20.91万
  • 财政年份:
    2013
  • 负责人:
    SUSANNE M ARNOLD
  • 依托单位:
海外基金